Path ID: DB09035_MESH_D002289_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C581771 | nivolumab | Drug |
| UniProt:Q15116 | Programmed cell death protein 1 | Protein |
| GO:0002418 | immune response to tumor cell | BiologicalProcess |
| MESH:D002289 | Non-small cell lung cancer | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Nivolumab | DECREASES ACTIVITY OF | Programmed Cell Death Protein 1 |
| Programmed Cell Death Protein 1 | NEGATIVELY REGULATES | Immune Response To Tumor Cell |
| Immune Response To Tumor Cell | NEGATIVELY CORRELATED WITH | Non-Small Cell Lung Cancer |
Comment: This drug is an example of immune checkpoint blockade. Programmed death 1 (PD-1) is a key immune-checkpoint receptor expressed by activated T cells, and it mediates immunosuppression. Inhibition of the PD-1 protein can enhance T-cell responses and mediate preclinical antitumor activity (https://pubmed.ncbi.nlm.nih.gov/22658127/).
Reference: